Media Articles Related to Zyflo CR (Zileuton)
Childhood asthma: Looking on the brighter side
Source: Respiratory / Asthma News From Medical News Today [2015.11.27]
The effect of a widespread genetic variant that increases the risk for childhood asthma can be neutralized.
Early childhood bronchiolitis increases asthma risk in adulthood
Source: Respiratory / Asthma News From Medical News Today [2015.11.24]
Persons who have had bronchiolitis in early childhood have an increased risk of asthma at the age of 28-31 and a weaker health-related quality of life than their peers.
Asthma Treatment Before School Cuts Exacerbations
Source: MedPage Today Allergy & Immunology [2015.11.24]
(MedPage Today) -- In this MedPage Today video report, David Lang, MD, explains the value of pretreatment
Allergy and Asthma Sufferers Beware as Holiday Season Kicks In
Source: MedicineNet Allergy Specialty [2015.11.23]
Title: Allergy and Asthma Sufferers Beware as Holiday Season Kicks In
Category: Health News
Created: 11/21/2015 12:00:00 AM
Last Editorial Review: 11/23/2015 12:00:00 AM
High levels of physical activity may worsen asthma control in young females
Source: Respiratory / Asthma News From Medical News Today [2015.11.19]
Among 526 adolescents and young adults who were asked about their exercise habits, those with asthma tended to report more physical activity than those without asthma.
Published Studies Related to Zyflo CR (Zileuton)
Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. [2011.02]
RATIONALE: Leukotrienes have been implicated in the pathogenesis of acute exacerbations of COPD, but leukotriene modifiers have not been studied as a possible therapy for exacerbations. OBJECTIVE: We sought to test the safety and efficacy of adding oral zileuton (a 5-lipoxygenase inhibitor) to usual treatment for acute exacerbations of COPD requiring hospitalization... CONCLUSIONS: While oral zileuton during COPD exacerbations that require hospital admission is safe and reduces urinary LTE(4) levels, we found no evidence suggesting that this intervention shortened hospital stay, with the limitation that our sample size may have been insufficient to detect a modest but potentially meaningful clinical improvement.
Randomized trial of zileuton for treatment of COPD exacerbations requiring
requiring hospitalization... CONCLUSIONS: While oral zileuton during COPD exacerbations that require
Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. [2007.08]
BACKGROUND: A controlled-release (CR) formulation of zileuton was developed to simplify administration from 600 mg 4 times daily (Zyflo) to 1,200 mg twice daily. OBJECTIVE: To evaluate the efficacy of zileuton CR, two 600-mg tablets twice daily, compared with placebo... CONCLUSIONS: Treatment with zileuton CR, 1,200 mg twice daily, resulted in a significant improvement in asthma control, and the safety and efficacy profile was similar to that observed with zileuton IR, 600 mg 4 times daily (Zyflo).
Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. [2007.06]
OBJECTIVE: To assess the therapeutic effects of oral zileuton tablets combined with low-dose beclomethasone compared to doubling the dose of beclomethasone, in improving lung function and reducing asthma symptoms... CONCLUSIONS: The addition of a 5-LO inhibitor added to low-dose beclomethasone may be an alternative to higher-doses of ICS in patients unable to achieve sufficient asthma control on low-dose ICS therapy.
The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. [2007.05]
This study was conducted to assess the safety and efficacy of zileuton controlled release [CR] 1,200 mg BID added to usual care (UC) in 926 patients with moderate asthma (619 patients randomized to zileuton CR and 307 to placebo). Sustained improvements in AM and PM peak expiratory flow (PEF) were observed in the zileuton CR group compared to placebo.
Clinical Trials Related to Zyflo CR (Zileuton)
Evaluating the Safety of Zileuton (Zyflo�) in Combination With Dasatinib (Sprycel�) in Chronic Myelogenous Leukemia [Recruiting]
Prospective nonrandomized phase I study
The purpose of this study is to determine safety and efficacy of zileuton when added to
dasatinib in patients with chronic myelogenous leukemia (CML).
Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. [Terminated]
The leukemic stem cells (LSCs) are cells that self- renew and give rise to leukemia.
Eradication of LSC is required for cure. In chronic myelogenous leukemia (CML) LSCs are not
eradicated by imatinib (Gleevec) alone. Recent discovery by Dr. Shaoguang Li at University
of Massachusetts indicates that the LSCs can be targeted by a new drug zileuton (Chen et al.
Nature Genetics 2009; 41: 783-792). Zileuton (approved for asthma) will be tested in a
combination with Gleevec. This combination has not been used previously to treat leukemia.
This is a Phase I study. The goal of this research is to evaluate the safety of the standard
anti-cancer drug imatinib and experimental drug zileuton.
Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers [Not yet recruiting]
This randomized phase II trial studies the effects of aspirin and zileuton on genes related
to tobacco use in current smokers. Smokers are at increased risk for developing lung and
other cancers. Aspirin and zileuton may interfere with genes related to tobacco use and may
be useful in preventing lung cancer in current smokers.
Trial of Zileuton CR in Children and Adults With Sickle Cell Disease [Completed]
The purpose of this research study is to test the safety of Zileuton and see what effects
(good and bad) it has on you, other children and adults with Sickle Cell Disease (SCD). The
investigators also want to see how Zileuton is handled by your body at different doses.
Zileuton is a drug that is approved by the Food and Drug Administration (FDA) for the
treatment of asthma for people age 12 and older. The FDA has not approved Zileuton for the
treatment of SCD, so it is being studied as an investigational drug for SCD through an
application to the FDA. In asthma patients, Zileuton helps by reducing inflammation. This
study will see if Zileuton helps to reduce inflammation associated with SCD.
Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers [Completed]
The goal of this clinical research study is to learn how zileuton alone or the combination
of zileuton and celecoxib may affect certain chemicals in the body that may be linked with a
risk for smoking-related lung disease. These effects will be measured by a urine test
Reports of Suspected Zyflo CR (Zileuton) Side Effects
Drug Ineffective (2),
Product Quality Issue (2),
Alanine Aminotransferase Increased (2),
Aspartate Aminotransferase Increased (2),
Blood Bilirubin Increased (1),
Fatigue (1), more >>